It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Allergies to grass pollen affects about 20% of the population worldwide. In the last few decades, the South American grass Cortaderia selloana (CS, Pampas grass) has expanded worldwide in a variety of countries including the USA, Australia and Western Europe. In many of these locations, CS has strikingly spread and has now been classified an invasive species. Many pernicious consequences of CS have been reported for local biodiversity, landscape and structures. However, the effect on human health has not been studied. To investigate this issue, we have chosen a European region on the northern cost of Spain where CS spread is overwhelming, Cantabria. We obtained CS pollen extract and analysed the allergenic reaction of 98 patients that were allergic to pollen of local grasses. We determined the skin reaction and the presence of specific IgE antibodies (sIgE) to CS or to a typical autochthonous grass, Phleum pratense. We also compared the seasonal symptoms with reported grass pollen counts in the area. The results strongly suggest that CS can cause respiratory allergies at a similar extent to the local grasses. Given that CS pollinises later than the local grasses, this would extend the period of grass allergies in the region for about three months every year, as stated by most of the patients. This is the first study reported on the effects of the striking expansion of CS on human health. Considering the strong impact that respiratory allergies have on the population, our results suggest that CS can currently constitute a relevant environmental health issue.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hospital Universitario Marqués de Valdecilla (HUM), Allergy Service, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)
2 ALK-Abelló S.A., CMC R&D Department, Madrid, Spain (GRID:grid.476084.9) (ISNI:0000 0004 0644 1034)
3 Institute for Research Marqués de Valdecilla, Santander, Spain (GRID:grid.476084.9)
4 Sierrallana Hospital, Allergy Service, Torrelavega, Spain (GRID:grid.411325.0)
5 University of the Basque Country (UPV/EHU), Department of Plant Biology and Ecology, Bilbao, Spain (GRID:grid.11480.3c) (ISNI:0000000121671098)
6 Asociación Cantabria Sin Plumeros, Liaño, Spain (GRID:grid.11480.3c)
7 Institute for Research Marqués de Valdecilla, Santander, Spain (GRID:grid.11480.3c); INSERM, Occitanie, Montpellier, France (GRID:grid.457377.5)